← FDA DRUG APPROVALS

FDA ANDA · ANDA207401

ACETAZOLAMIDE EXTENDED-RELEASE

Sponsor: MICRO LABS LTD INDIA

APPLICATION
ANDA207401
TYPE
ANDA
ORIGINAL APPROVAL
2020-10-01
LATEST ACTION
2024-11-26
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

ACETAZOLAMIDEPrescription
ACETAZOLAMIDE 500MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2024-11-26Labeling · Supplement 2 · standardAP
2023-05-19Labeling · Supplement 1 · standardAP
2020-10-01UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →